Literature DB >> 21519343

DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.

O Abdel-Wahab, A Pardanani, R Rampal, T L Lasho, R L Levine, A Tefferi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21519343      PMCID： PMC4640464          DOI： 10.1038/leu.2011.82

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  5 in total

1.  Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.

Authors:  O Abdel-Wahab; A Pardanani; J Patel; M Wadleigh; T Lasho; A Heguy; M Beran; D G Gilliland; R L Levine; A Tefferi
Journal:  Leukemia       Date:  2011-04-01       Impact factor: 11.528

2.  Array-based genomic resequencing of human leukemia.

Authors:  Y Yamashita; J Yuan; I Suetake; H Suzuki; Y Ishikawa; Y L Choi; T Ueno; M Soda; T Hamada; H Haruta; S Takada; Y Miyazaki; H Kiyoi; E Ito; T Naoe; M Tomonaga; M Toyota; S Tajima; A Iwama; H Mano
Journal:  Oncogene       Date:  2010-04-19       Impact factor: 9.867

3.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

4.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

5.  Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.

Authors:  M J Walter; L Ding; D Shen; J Shao; M Grillot; M McLellan; R Fulton; H Schmidt; J Kalicki-Veizer; M O'Laughlin; C Kandoth; J Baty; P Westervelt; J F DiPersio; E R Mardis; R K Wilson; T J Ley; T A Graubert
Journal:  Leukemia       Date:  2011-03-18       Impact factor: 11.528
  5 in total
  57 in total

Review 1.  Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.

Authors:  Su-Jiang Zhang; Omar Abdel-Wahab
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

2.  Recurring mutations in myeloproliferative neoplasms alter epigenetic regulation of gene expression.

Authors:  Gary W Reuther
Journal:  Am J Cancer Res       Date:  2011-05-29       Impact factor: 6.166

3.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

Review 4.  Perspectives and future directions for epigenetics in hematology.

Authors:  Margaret A Goodell; Lucy A Godley
Journal:  Blood       Date:  2013-05-21       Impact factor: 22.113

Review 5.  Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).

Authors:  Wenyi Luo; Zhongxin Yu
Journal:  Stem Cell Investig       Date:  2015-08-31

6.  Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.

Authors:  Dongqing Yan; Anthony D Pomicter; Srinivas Tantravahi; Clinton C Mason; Anna V Senina; Jonathan M Ahmann; Qiang Wang; Hein Than; Ami B Patel; William L Heaton; Anna M Eiring; Phillip M Clair; Kevin C Gantz; Hannah M Redwine; Sabina I Swierczek; Brayden J Halverson; Erkan Baloglu; Sharon Shacham; Jamshid S Khorashad; Todd W Kelley; Mohamed E Salama; Rodney R Miles; Kenneth M Boucher; Josef T Prchal; Thomas O'Hare; Michael W Deininger
Journal:  Clin Cancer Res       Date:  2018-12-18       Impact factor: 12.531

7.  Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.

Authors:  Ayalew Tefferi; Pierre Noel; Curtis A Hanson
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

8.  Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients.

Authors:  E Masselli; C Carubbi; G Gobbi; P Mirandola; D Galli; S Martini; S Bonomini; M Crugnola; L Craviotto; F Aversa; M Vitale
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

Review 9.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

10.  Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.

Authors:  Véronique Gelsi-Boyer; Nathalie Cervera; François Bertucci; Mandy Brecqueville; Pascal Finetti; Anne Murati; Christine Arnoulet; Marie-Joelle Mozziconacci; Ken I Mills; Nicholas C P Cross; Norbert Vey; Daniel Birnbaum
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.